AU4580301A - Cephalotaxine alkaloid compositions and uses thereof - Google Patents

Cephalotaxine alkaloid compositions and uses thereof

Info

Publication number
AU4580301A
AU4580301A AU4580301A AU4580301A AU4580301A AU 4580301 A AU4580301 A AU 4580301A AU 4580301 A AU4580301 A AU 4580301A AU 4580301 A AU4580301 A AU 4580301A AU 4580301 A AU4580301 A AU 4580301A
Authority
AU
Australia
Prior art keywords
cephalotaxine
agents
hydroxy
host
proliferative disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU4580301A
Other languages
English (en)
Inventor
Dennis M Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ChemGenex Pharmaceuticals Inc
Original Assignee
ChemGenex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ChemGenex Therapeutics Inc filed Critical ChemGenex Therapeutics Inc
Publication of AU4580301A publication Critical patent/AU4580301A/xx
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU4580301A 2000-03-15 2001-03-15 Cephalotaxine alkaloid compositions and uses thereof Pending AU4580301A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18969900P 2000-03-15 2000-03-15
PCT/US2001/008480 WO2001068098A2 (en) 2000-03-15 2001-03-15 Cephalotaxine alkaloid combination compositions and uses thereof

Publications (1)

Publication Number Publication Date
AU4580301A true AU4580301A (en) 2001-09-24

Family

ID=22698410

Family Applications (2)

Application Number Title Priority Date Filing Date
AU4580301A Pending AU4580301A (en) 2000-03-15 2001-03-15 Cephalotaxine alkaloid compositions and uses thereof
AU2001245803A Ceased AU2001245803B8 (en) 2000-03-15 2001-03-15 Cephalotaxine alkaloid compositions and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001245803A Ceased AU2001245803B8 (en) 2000-03-15 2001-03-15 Cephalotaxine alkaloid compositions and uses thereof

Country Status (11)

Country Link
US (4) US6734178B2 (enExample)
EP (1) EP1263440B1 (enExample)
JP (1) JP4929436B2 (enExample)
AT (1) ATE330611T1 (enExample)
AU (2) AU4580301A (enExample)
CA (1) CA2402710A1 (enExample)
DE (1) DE60120928T2 (enExample)
DK (1) DK1263440T3 (enExample)
ES (1) ES2267741T3 (enExample)
PT (1) PT1263440E (enExample)
WO (1) WO2001068098A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE330611T1 (de) * 2000-03-15 2006-07-15 Chemgenex Pharmaceuticals Inc Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung
US20060211648A1 (en) * 2000-04-12 2006-09-21 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
DE60113666T2 (de) * 2000-04-12 2006-06-14 Chemgenex Pharmaceuticals Inc Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten
US7135481B2 (en) 2000-04-12 2006-11-14 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
AU2002246542A1 (en) * 2000-10-31 2002-07-30 Chemgenex Therapeutics, Inc. Antiproliferative colchicine compositions and uses thereof
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
EP1487434B1 (en) * 2002-03-06 2007-05-09 The Medical Research and Education Trust Botanical extract compositions with anti-cancer activity comprising isoliquiritigenin
CA2492456A1 (en) * 2002-07-17 2004-01-29 Dennis M. Brown Formulations and methods of administration of cephalotaxines, including homoharringtonine
WO2004009030A2 (en) * 2002-07-22 2004-01-29 Chemgenex Pharmaceuticals Limited Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
CN100396286C (zh) * 2002-12-30 2008-06-25 北京大学第一医院 高三尖杉酯碱和三尖杉酯碱在制备抑制血管生成药物中的应用
EP1765341A4 (en) * 2004-06-04 2010-04-14 Chemgenex Pharmaceuticals Inc PROCESS FOR TREATING PROLIFERATIVE CELL DISEASE USING NAPHTHALIMIDE AND PARP-1 INHIBITORS
CA2597323A1 (en) * 2005-02-10 2006-08-17 Chemgenex Pharmaceuticals, Inc. Medical devices
AU2008240044B2 (en) * 2007-04-13 2013-09-12 Teva Pharamceuticals International Gmbh Oral cephalotaxine dosage forms
EP2260041A4 (en) 2008-03-03 2012-04-25 Sloan Kettering Inst Cancer CEPHALOTAXUS ESTERS, METHOD FOR THEIR SYNTHESIS AND USES THEREOF
CN118217301B (zh) * 2024-03-28 2025-08-05 宁波大学附属人民医院 一种协同治疗aml的含有8-氯腺苷和高三尖杉酯碱的药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4675318A (en) * 1985-05-28 1987-06-23 Yaguang Liu Safe antileukemia drug, SAL
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
ATE330611T1 (de) * 2000-03-15 2006-07-15 Chemgenex Pharmaceuticals Inc Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung
DE60113666T2 (de) * 2000-04-12 2006-06-14 Chemgenex Pharmaceuticals Inc Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten

Also Published As

Publication number Publication date
JP4929436B2 (ja) 2012-05-09
DE60120928D1 (de) 2006-08-03
AU2001245803B2 (en) 2005-12-15
WO2001068098A2 (en) 2001-09-20
DE60120928T2 (de) 2007-02-08
US20020032190A1 (en) 2002-03-14
HK1052138A1 (en) 2003-09-05
US20040185117A1 (en) 2004-09-23
US20120207855A1 (en) 2012-08-16
US6734178B2 (en) 2004-05-11
AU2001245803B8 (en) 2006-02-02
US20110008307A1 (en) 2011-01-13
JP2003526667A (ja) 2003-09-09
CA2402710A1 (en) 2001-09-20
DK1263440T3 (da) 2006-10-23
EP1263440B1 (en) 2006-06-21
ATE330611T1 (de) 2006-07-15
EP1263440A2 (en) 2002-12-11
PT1263440E (pt) 2006-11-30
ES2267741T3 (es) 2007-03-16
WO2001068098A3 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
AU4580301A (en) Cephalotaxine alkaloid compositions and uses thereof
WO2000072799A3 (en) Method and compositions for treating the inflammatory response
AP2001002319A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
AU5348301A (en) Naphthalimide compositions and uses thereof
NO20020662D0 (no) Pyrimidin-2,4,6-trion metalloproteinase inhibitorer
HUP0200410A3 (en) Pharmaceutical compositions for improving fertility using inhibitors of dipeptidyl peptidase in
AP1411A (en) Pyrrolo[2,3d] pyrimidine compositions and their use.
ZA200104697B (en) Compositions and methods for amelioration of human female sexual dysfunction.
BR0010220A (pt) Compostos de pirimidinona
MY141651A (en) Nep inhibitors for the treatment of female sexual dysfunction
BG102879A (en) Carbolin derivatives
BR0114829A (pt) Novos compostos
PL368286A1 (en) Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
WO2000066180A3 (en) Method for enhancing contrast produced by mri
WO2003022216A3 (en) Biaryl substituted purine derivatives as potent antiproliferative agents
AU2001287157A1 (en) Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
FR2792938B1 (fr) NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
PT1075477E (pt) Novos n-oxidos de benzonaftiridina
AU1783201A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
MY129445A (en) Compositions for treating inflammatory response
AU2002239277A1 (en) Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions and method of use thereof
WO2001087288A8 (en) Method of treating vaginal dryness with nicotinic acetylcholine receptor agonists
WO2001091741A3 (en) Compositions containing hexitol and an antiproliferative agent
EP1235814A4 (en) 3,4-DIHYDRO- (1H) QUINAZOLINE-2-ONE COMPOUNDS FOR USE AS CSBP / p38 KINASE INHIBITORS
IL164151A0 (en) 6-(4-Substituted-anilino)pyrimidine derivatives, method for preparation thereof and antiviral pharmaceutical composition comprising